Forty-nine states have begun the activity necessary to have health insurance exchanges operational by 2014.
For those individuals and families between 133% and 400% of federal poverty level (FPL) who purchase individual market insurance products through the health benefit exchanges, federal subsidies will be available. In many states, certain populations above 133% of FPL are eligible currently for Medicaid. Now these states will need to decide the break point between Medicaid and exchange-subsidized insurance.
MILLIONS EXPECTED TO CHURN
If these individuals take part-time or other work with no benefits, and their income rises above the Medicaid threshold, they shift from Medicaid to the exchange to buy federally subsidized policies. A recent study by Harvard and George Washington University showed that as many as 28 million individuals could be expected to churn among these programs in the first year exchanges are operational.
Exchanges must be designed as part of the continuum of insurance within the state. States are considering several options:
Over the next two years, as states design exchanges and revisit their Medicaid programs, the challenges of churn are certain to be front and center in any discussion on program design.
This column is written for informational purposes only and should not be construed as legal advice.
Cindy Gillespie is managing director for McKenna Long & Aldridge LLP.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More